Dr. Dalton on the Future Treatment of Gynecologic Malignancies

Heather Dalton, MD
Published: Wednesday, May 31, 2017



Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses the future of treatment for gynecologic malignancies.

Dalton believes that platinum-based therapy and taxanes will remain the backbone of treatment for this disease. However, with the newest knowledge of BRCA and PARP inhibitors, she says, this landscape will hopefully have a stronger maintenance strategy.
 
SELECTED
LANGUAGE


Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses the future of treatment for gynecologic malignancies.

Dalton believes that platinum-based therapy and taxanes will remain the backbone of treatment for this disease. However, with the newest knowledge of BRCA and PARP inhibitors, she says, this landscape will hopefully have a stronger maintenance strategy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x